John E. Gallagher was named Chief Financial Officer of CONMED Corp. As of November 6, 2026, CONMED Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 20, 2026 to June 17, 2026, naming 4 appointments (Form 8-K, June 17, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like CONMED Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CONMED Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-20 to 2026-06-17. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as CONMED Corp files it.
Also on the record for CONMED Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.25% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.87% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 3.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Fuller & Thaler Asset Management, Inc. | 5.63% of the class | 5%+ stakes | Source |
| July 18, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 15.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CONMED Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on CONMED Corp and the records around it.
CONMED Corp elsewhere on the record
Companies that share a holder
- Fuller & Thaler Asset Management, Inc. also filed stake reports on 35 other companies: COLLEGIUM PHARMACEUTICAL, INC (Aug 2026), Graphic Packaging Holding Co (Aug 2026), Primoris Services Corp (Aug 2026)
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
Watch CONMED Corp
Get an email when CONMED Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CONMED Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CONMED Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CONMED Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-17 | In | Chief Financial Officer | 8-K, 2026-06-17 | ||
| 2026-05-20 | In | Director | 2026-07-01 | 8-K, 2026-05-20 | |
| 2026-05-20 | In | 8-K, 2026-05-20 | |||
| 2026-05-20 | In | Controller | 2026-06-01 | 8-K, 2026-05-20 |
Who leads CONMED Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Celine Martin, appointed, effective 2026-07-01 (filed 2026-05-20).
- Chief Financial Officer: John E. Gallagher, appointed (filed 2026-06-17).
- Controller: Kimberly Lockwood, appointed, effective 2026-06-01 (filed 2026-05-20).
New leaders reset buying decisions — get the Full Report on CONMED Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at CONMED Corp, with the record behind each one.
Find candidates like Chief Financial Officer at CONMED CorpEvery change, in the filing's words
Appointed: John E. Gallagher, Chief Financial Officer
On June 17, 2026, CONMED Corporation (the "Company") announced that John E. Gallagher has been appointed to serve as the Company's Executive Vice President, Chief Financial Officer beginning July 15, 2026 (the "Effective Date").
- Mr. Gallagher will also be the Company's principal financial officer and principal accounting officer.
- Mr. Gallagher, age 53, will join the Company from Certara, Inc., a publicly traded pharmaceutical technology and services company, where he has served as Chief Financial Officer since April 2023.
- Prior to joining Certara, Mr. Gallagher served as Chief Financial Officer of Cue Health Inc., a publicly traded healthcare technology company, from 2021 to 2023.
- Prior to Cue Health, Mr. Gallagher served as Senior Vice President, CFO of the Medical Segment and Treasurer of Becton, Dickinson & Co., a multinational medical technology company.
- Mr. Gallagher joined Becton Dickinson in 2012 as Corporate Treasurer and also served as Chief Accounting Officer during his time there.
- Prior to joining Becton Dickinson, Mr. Gallagher served in a variety of finance leadership positions at NBC Universal, General Electric Company and Ford Motor Company.
- Mr. Gallagher received his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and a B.S. in Finance from Clemson University.
- Mr. Gallagher's annual base salary will be $650,000, and he will be eligible for an annual cash bonus targeted at 85% of his base salary, subject to achievement of certain performance metrics.
Appointed: Celine Martin, Director, effective 2026-07-01
Appointment of Non-Employee Directors On May 19, 2026, the Board of Directors (the "Board") of CONMED Corporation (the "Company") increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
Appointed: Celine Martin
Ms. Martin was appointed to the Audit Committee and the Strategy Committee.
Appointed: Kimberly Lockwood, Controller, effective 2026-06-01
On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.
- Ms. Martin and Mr. Mirviss will each serve a term until the Company's 2027 annual meeting of stockholders and a respective successor has been duly elected and qualified, or until such director's earlier termination of service.
- Mr. Mirviss was appointed to the Compensation Committee and the Corporate Governance and Nominating Committee.
- The Board determined that Ms. Martin and Mr. Mirviss are independent in accordance with the requirements of the New York Stock Exchange.
- In addition, the Board has affirmatively determined that Ms. Martin and Mr. Mirviss qualify as independent in accordance with the additional independence rules established by the Securities and Exchange Commission (the "SEC") and the NYSE.
- There are no understandings or arrangements between Ms. Martin, Mr. Mirviss or any third parties pursuant to which they each were selected as a director.
- In addition, neither Ms. Martin nor Mr. Mirviss have any familial relationship with any director or executive officer of the Company.
- Over three decades at Johnson & Johnson, both in the U.S. and internationally, Ms. Martin played a vital role in advancing the ambition of J&J MedTech, developing new categories and advancing standard of care for atrial fibrillation, stroke, and minimally invasive surgery.
Tools for this story
Each opens in a new tab, filled in for CONMED Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.